More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-N-BE(2)-M17: Human Neuroblastoma Cell Line



SK-N-BE(2)-M17 is a twice-sub-cloned cell line derived from the SK-N-BE(2) neuroblastoma cell line. Like the parental cell line, these cells display MYCN amplification. Treatment with trans-retinoic acid differentiates these cells into a distinct neuronal phenotype. These cells display high levels of tyrosine hydroxylase activity and moderate dopamine-b-hydroxylase activity.


This cell line is a subclone of the SK-N-BE(2) neuroblastoma cell line. The parental cell line was established in 1972 from a metastatic site (bone marrow) in a two-year-old Caucasian male with malignant neuroblastoma.


  • June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering
  • Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Ciccarone V et al. (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Research 49: 219-225 (PubMed ID: 2535691)
  • Andres D et al. (2013) Morphological and functional differentiation in BE(2)-M17 human neuroblastoma cells by treatment with trans-retinoic acid. BMC Neuroscience 14: 49 (PubMed ID: 23597229)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078,
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354,

Stage of Development

Ready to use